-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen

Benzinga·11/17/2026 06:31:04
  • Benefits of continuous lecanemab treatment in early Alzheimer’s disease accrue over time
  • Lecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI
  • 62% of patients with low tau showed improvement in cognitive function and activities of daily living (CDR-SB) at five years